Infant Bacterial Therapeutics
Develops microbiome drugs to prevent or treat rare diseases in premature infants.
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Manufacturing
Description
Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-28 18:52 |
IBT beviljas “Breakthrough Therapy Designation” för sin läkemedelskandidat
|
Swedish | PDF • 61.4 KB | ||
| 2025-03-28 18:52 |
IBT is granted Breakthrough Therapy Designation for its Drug Candidate
|
English | PDF • 60.1 KB | ||
| 2025-03-27 08:00 | English | HTML • 2.6 MB | |||
| 2025-03-27 08:00 | English | HTML • 2.6 MB | |||
| 2025-02-13 08:30 | Swedish | PDF • 577.8 KB | |||
| 2025-02-13 08:30 | English | PDF • 571.2 KB | |||
| 2024-11-14 08:30 | Swedish | PDF • 1009.2 KB | |||
| 2024-11-14 08:30 | English | PDF • 1.0 MB | |||
| 2024-10-09 09:00 |
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsst…
|
Swedish | PDF • 39.5 KB | ||
| 2024-10-09 09:00 |
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomina…
|
English | PDF • 39.8 KB | ||
| 2024-08-30 18:38 |
IBTs fas III-studie visar inga signifikanta effekter på de primära effektmåtten…
|
Swedish | PDF • 54.0 KB | ||
| 2024-08-30 18:38 |
IBT's phase III study shows no significant effects on the primary endpoints but…
|
English | PDF • 54.2 KB | ||
| 2024-08-28 08:30 | Swedish | PDF • 578.3 KB | |||
| 2024-08-28 08:30 | English | PDF • 594.7 KB | |||
| 2024-08-15 16:44 |
Infant Bacterial Therapeutics patent godkänt i USA
|
Swedish | PDF • 48.9 KB |
Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Infant Bacterial Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-05-04 | Anders Kronström | Other | Buy | 1,650 | 157,179.00 SEK |
| 2021-05-04 | Staffan Strömberg | Other | Buy | 1,500 | 145,050.00 SEK |
| 2021-05-04 | Peter Rothschild | Other | Buy | 100,000 | 9,330,000.00 SEK |
| 2021-03-26 | Anders Kronström | Other | Buy | 3,500 | 350,000.00 SEK |
| 2021-03-15 | Daniel Patrick Mackey | Other | Sell | 400 | 41,200.00 SEK |
| 2021-03-12 | Daniel Patrick Mackey | Other | Buy | 400 | 41,800.00 SEK |
| 2021-02-05 | Olof Anthon Jahreskog | Other | Buy | 1,000 | 118,140.00 SEK |
| 2020-03-16 | Anders Kronström | Other | Buy | 863 | 53,623,368.00 SEK |
Peer Companies
